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Damned If You Do and Damned If You Don’t“These patients say they cannot afford to wait for research results
because they will wind up in wheelchairs before the studies are
done. Their only option, so far, has been a lifelong course of drugs
with limited beneﬁts and harsh side-effects. To some, balloon
treatment seems no riskier than those drugs”
Denise Grady, New York Times1
In the two years since Zamboni2 proposed that chronic cerebro-
spinal venous insufﬁciency (CCSVI) secondary to stenosis or occlu-
sion of the internal jugular or azygous veins might be a treatable
cause of multiple sclerosis (MS), the subject has become one of
the most controversial in medicine. A Google search for CCSVI
yielded no fewer than 178,000 hits, mostly representing adverts
for private interventions, internet blogs, pressure groups and Face-
book pages, relentlessly exposing the vulnerability, anger and
deeply held frustrations of MS patients.1,3 As far as they are con-
cerned, they have little to lose. Research, the medical profession
and MS charities have completely failed them. According to Chafe
(in a provocative commentary in the journal Nature),3 some
patients have even accused the MS Society and MS Physicians “of
being swayed by conﬂicts of interest because when treatment of CCSVI
is introduced, the number of MS patients will drop”. Not surprisingly,
therefore, the emerging vox populi message seems to be that the
available (albeit anecdotal) evidence is believed by many MS
patients to support venoplasty; that randomised trials will take
too long (as well as being unnecessary) and that many would be
happy to consent to a procedure that is perceived to have fewer
side-effects than the medications they currently take, even if the
beneﬁts only last for a short period of time.
Conversely, the very mention of CCSVI elicits polarised opinions
within the medical profession; not least because of the pervasive
email campaign through which ‘faceless’ lobbyists urge doctors to
be more vigorous in their support of venoplasty in MS patients.
At one extreme, private clinics advertise on the internet to vulner-
able patients and offer tantalisingly good patient testimonials,
whilst espousing the beneﬁts (and safety) of venoplasty. One oft
quoted justiﬁcation is that venoplasty is an accepted interventional
strategy for other central venous pathologies that have not been
subjected to randomised comparison, sowhy should it be restricted
in MS patients? There have been only two recorded venoplasty
related deaths,4,5 but Vascular Units are now beginning to report
new types of complication in patients who have travelled to other
countries to be treated,6 primarily because the procedure is banned
in their own.
At the other extreme, opponents of the move towards unregu-
lated venoplasty cite the lack of quality evidence that CCSVI actually1078-5884/$ – see front matter  2011 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2011.10.020exists and that those performing venoplasty are (in effect) exploit-
ing vulnerable patients. Most believe that it is, therefore, unethical
to perform randomised trials because no-one has conclusively
proved that CCSVI is a proven cause of MS.
It is also true that relatively few studies have been able to repli-
cate Zamboni’s original ﬁndings (which reported a near unprece-
dented 100% speciﬁcity and sensitivity),2 although some have, at
least, partially corroborated the CCSVI theory.7 However, a PubMed
review of research papers published in 2011 only identiﬁed one
(albeit quite large) study that broadly supported the CCSVI
hypothesis,7 whilst six other studies did not.8–13 The lack of
conclusive evidence supporting the CCSVI hypothesis has led the
Cardiovascular and Interventional Radiological Society of Europe
(CIRSE) to advise against venoplasty in MS patients,14 while other
regulatory and professional bodies recommend that it should not
be considered outwith properly conducted and ethically approved
research trials.15,16 However, in a commentary in the journal
Nature, Chafe suggests that while “the dominant paradigm is that
an interventional trial is not justiﬁed unless there is a strong biologic
rationale”, it may be that “in today’s era of ‘Facebook equipoise’, it
may make sense in rare cases to conduct a clinical trial before the
desired weight of scientiﬁc evidence is available”.3 He concluded
that; “if the results (of observational studies) are delayed or are
unconvincing to many patients, we believe that the beneﬁts of
a double-blinded randomized trial would outweigh the costs,
including the diversion of resources from other priorities”. This
clearly represents a very radical change in the way trials are
undertaken and is perhaps indicative of the future power of the
‘social media’ to inﬂuence practice.
The strength of these contradictory opinions is also apparent
within the current issue of the European Journal of Vascular and
Endovascular Surgery which includes the results of a pilot study
from Zamboni et al.17 Although under-powered, he suggests that
immediate therapy with venoplasty (whilst associated with a 27%
restenosis rate), was associated with a signiﬁcant reduction in
annualized relapse rates (compared to patients receiving veno-
plasty after 6 months of medical therapy) as well as a trend towards
fewer T2 lesions on MRI in patients undergoing immediate treat-
ment. Given the history of this debate, the Editors felt it appropriate
to commission a wide variety of commentaries to accompany this
paper. As will be seen, the opinions of our commentators truly
reﬂect the polarised opinions of Society as awhole. Some are highly
critical, whilst one is supportive. One important message, however,
might be the potential role of blindedMRI analysis of the number of
new T2 lesions as being an objective means of evaluating outcomes
in any future randomised trials.d by Elsevier Ltd. All rights reserved.
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doubts of MS patients that politicians and doctors don’t care), the
Canadian Government has recently agreed to fund $2.4 million
towards a series of studies relating to CCSVI,18 while in the UK;
NICE has called for research (preferably including a sham interven-
tion arm) to be undertaken as a matter of priority.15 To-date,
however, only two studies in the world are recruiting into a rando-
mised trial evaluating venoplasty against sham intervention that
are currently registered with Clinicaltrials.gov. Interestingly, both
of these studies are based at Albany, New York (Clinicaltrials.gov
Identiﬁers: NCT01089686 and NCT01201707). Given the potential
problems with recruiting desperate and anxious MS patients
(who really only want to undergo venoplasty), it might prove difﬁ-
cult to recruit enough patients to complete both studies. Accord-
ingly, it does seem somewhat unfortunate that they cannot
collaborate within one protocol.
Notwithstanding the grave concerns held by those who are
opposed to performing venoplasty inMS patients, the Editors agree
that it is important that ‘evidence based practice’ rather than ‘Face-
book based practice’ determines how we should treat MS patients
in the future. To paraphrase Robert Fox and Alex Rae-Grant; “It
behoves the clinical research community to carefully pursue CCSVI to
its end. We should neither jump on the bandwagon as it passes
through town, nor assiduously miss the parade”.19
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